Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BYFrontiers in bioengineering and biotechnology

Natural polysaccharide-engineered POP@ZIF-67 nanoparticles coordinate antibacterial activity, macrophage polarization, and osteogenesis for chronic osteomyelitis therapy.

  1. 1Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
  2. 2Hubei Provincial Clinical Medical Research Center for Trauma and Microsurgery, Wuhan, China.

Abstract

Chronic osteomyelitis is difficult to treat due to the interplay of bacterial colonization, excessive inflammation, and impaired bone regeneration. Here, we developed an engineered natural polysaccharide POP@ZIF-67 nanoplatform to modulate these interrelated pathological processes. ZIF-67 is an antimicrobial framework with porous properties, peroxidase-like catalytic activity, and acid-responsive release behavior; purslane polysaccharide (POP) was incorporated as an immunomodulatory component to mitigate the excessive inflammatory stimulation induced by ZIF-67. POP@ZIF-67 exhibits effective antibacterial and antibiofilm activity against Staphylococcus aureus; more importantly, the incorporation of POP transforms the biological action of ZIF-67 from primarily antibacterial stimulation into a multifunctional platform capable of suppressing excessive M1-like macrophage responses, promoting repair-related polarization, and improving the osteogenic microenvironment. In a mouse model of chronic osteomyelitis, POP@ZIF-67 reduced local bacterial load and inflammatory damage while promoting collagen deposition, bone remodeling, and osteogenic maturation, without significant systemic toxicity. Overall, the study introduces an "antimicrobial framework-immune buffering" strategy that reconciles the antimicrobial efficacy of metal-organic frameworks with their immunostimulatory limitations. By integrating various therapeutic approaches, POP@ZIF-67 provides a promising new synthetic paradigm for the treatment of chronic osteomyelitis and infectious bone defects.

Related

  1. Astragalus Polysaccharide Hydrogel Promotes Diabetic Wound Healing by Modulating Macrophage Polarization and the Immune Microenvironment
    Leizi Chai, Peiji Lu, Wenhui Liu +5
    Journal of Inflammation ResearchPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMCEurope PMC
  2. Chitosan polymeric nanoparticles loaded with a grapefruit-derived flavonoid-rich extract containing naringenin: antibacterial activity, cytotoxicity evaluation and DFT interaction analysis
    Waad M. Al-Tawarh, Ruba H. Aldehayyat, Aziz Arzine +13
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textPharmacology & toxicologyCrossrefHAL
  3. Bioinspired conductive and antibacterial hydrogel bionanocomposite based on tragacanth gum, polyaniline and osteoconductive SiO2 nanoparticles as a scaffold for bone tissue engineering application
    Ali Khalaji, Soheila Zare, Faranak Aghaz +2
    Scientific ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ
  4. Antibacterial activity of imipenem-encapsulated chitosan/HPMCP nanoparticles against clinical Acinetobacter baumannii isolates.
    Sajad Alizadeh, Majid Baseri Salehi, Nima Bahador
    BMC infectious diseasesPeer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyEurope PMCDOAJ
  5. Total calcanectomy in chronic osteomyelitis of calcaneus: A case report
    Kumar Shantanu Anand, Rakhee Anand, Gyan Ranjan
    SICOT-JPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
BibTeX
@article{zhao2026natural,
  title = {{Natural polysaccharide-engineered POP@ZIF-67 nanoparticles coordinate antibacterial activity, macrophage polarization, and osteogenesis for chronic osteomyelitis therapy.}},
  author = {Yunchang Zhao and Guangting Zhu and Mengxue Zhang and Yize Wu and Junwei Su and Jing Hu and Chao Jian and Ying Yuan},
  journal = {Frontiers in bioengineering and biotechnology},
  year = {2026},
  month = oct,
  doi = {10.3389/fbioe.2026.1935416},
  url = {https://europepmc.org/article/MED/42909020},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Natural polysaccharide-engineered POP@ZIF-67 nanoparticles coordinate antibacterial activity, macrophage polarization, and osteogenesis for chronic osteomyelitis therapy.
AU  - Yunchang Zhao
AU  - Guangting Zhu
AU  - Mengxue Zhang
AU  - Yize Wu
AU  - Junwei Su
AU  - Jing Hu
AU  - Chao Jian
AU  - Ying Yuan
PY  - 2026
DA  - 2026/10/07
JO  - Frontiers in bioengineering and biotechnology
DO  - 10.3389/fbioe.2026.1935416
UR  - https://europepmc.org/article/MED/42909020
AB  - Chronic osteomyelitis is difficult to treat due to the interplay of bacterial colonization, excessive inflammation, and impaired bone regeneration. Here, we developed an engineered natural polysaccharide POP@ZIF-67 nanoplatform to modulate these interrelated pathological processes. ZIF-67 is an antimicrobial framework with porous properties, peroxidase-like catalytic activity, and acid-responsive release behavior; purslane polysaccharide (POP) was incorporated as an immunomodulatory component to mitigate the excessive inflammatory stimulation induced by ZIF-67. POP@ZIF-67 exhibits effective antibacterial and antibiofilm activity against Staphylococcus aureus; more importantly, the incorporation of POP transforms the biological action of ZIF-67 from primarily antibacterial stimulation into a multifunctional platform capable of suppressing excessive M1-like macrophage responses, promoting repair-related polarization, and improving the osteogenic microenvironment. In a mouse model of chronic osteomyelitis, POP@ZIF-67 reduced local bacterial load and inflammatory damage while promoting collagen deposition, bone remodeling, and osteogenic maturation, without significant systemic toxicity. Overall, the study introduces an "antimicrobial framework-immune buffering" strategy that reconciles the antimicrobial efficacy of metal-organic frameworks with their immunostimulatory limitations. By integrating various therapeutic approaches, POP@ZIF-67 provides a promising new synthetic paradigm for the treatment of chronic osteomyelitis and infectious bone defects.
SN  - 2296-4185
ER  -